Squarepoint
NAMS icon

Squarepoint’s NewAmsterdam Pharma NAMS Stock Holding History

Squarepoint’s Portfolio NAMS Stock Details NAMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.12M Buy
92,026
+49,005
+114% +$1.61M ﹤0.01% 1982
2026
Q1 		$1.38M Buy
43,021
+12,202
+40% +$397K ﹤0.01% 2491
2025
Q4 		$1.08M Buy
30,819
+9,860
+47% +$359K ﹤0.01% 2536
2025
Q3 		$596K Buy
20,959
+6,680
+47% +$160K ﹤0.01% 3107
2025
Q2 		$259K Buy
+14,279
New +$260K ﹤0.01% 3795
2024
Q4 		– Sell
-17,133
Closed -$284K – 5351
2024
Q3 		$284K Buy
+17,133
New +$296K ﹤0.01% 3480

Other funds holding NAMS

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
DFO
Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return

Squarepoint's NAMS Position: Q2 2026 in Review

Squarepoint increased its NewAmsterdam Pharma (NAMS) stake by 114% in Q2 2026, buying an estimated $1.61M and bringing the position to 92,026 shares worth $3.12M. The position accounts for ﹤0.01% of the portfolio, ranked #1982.

Squarepoint first reported a position in NAMS in Q3 2024 and has held it in 6 quarters since. 195 funds tracked by Wall St. Rank hold NAMS as of Q2 2026.

  • Squarepoint held 92,026 shares of NewAmsterdam Pharma worth $3.12M as of Q2 2026.
  • Squarepoint bought 49,005 NewAmsterdam Pharma shares in Q2 2026, an estimated $1.61M.
  • NewAmsterdam Pharma made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #1982 holding.
  • Squarepoint first reported a position in NewAmsterdam Pharma in Q3 2024 and has held it in 6 quarters since.
  • 195 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.